NCT02901951View on ClinicalTrials.gov

Long-term Persistence of Immunity to Hepatitis B in Adults Vaccinated With GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine (HBV), Engerix-B

PHASE4CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

October 11, 2016

Primary Completion Date

May 1, 2017

Study Completion Date

May 1, 2017

Conditions
Hepatitis B Vaccine
Interventions
BIOLOGICAL

Engerix-B

Intramuscular administration of single challenge dose of Engerix-B vaccine in the deltoid region of the non-dominant arm.

Trial Locations (4)

2610

GSK Investigational Site, Wilrijk

9000

GSK Investigational Site, Ghent

G1E 7G9

GSK Investigational Site, Québec

J1H 2G2

GSK Investigational Site, Sherbrooke

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02901951 - Long-term Persistence of Immunity to Hepatitis B in Adults Vaccinated With GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine (HBV), Engerix-B | Biotech Hunter | Biotech Hunter